US-HEALTH-PEOPLE-RESEARCH-CANCER-pharmaceutical : News Photo
US-HEALTH-PEOPLE-RESEARCH-CANCER-pharmaceutical : News Photo
Embed
{{textForToggleButton('937109182')}}

US-HEALTH-PEOPLE-RESEARCH-CANCER-pharmaceutical

Test tubes are seen in the lab of Dr. Christian Hinrichs, an investigator at the National Cancer Institute in immunotherapy for HPV+ cancers, at the National Institutes of Health (NIH) in Bethesda, Maryland, February 7, 2018. Experimental trials are ongoing at the National Institutes of Health Clinical Center, a US government-funded research hospital where doctors are trying to partially replace patients' immune systems with T-cells that would specifically attack cancers caused by the human papillomavirus (HPV), a common sexually transmitted infection. A person's T-cells will naturally try to kill off any invader, including cancer, but usually fall short because tumors can mutate, hide, or simply overpower the immune system. Immunotherapies that have seen widespread success, such as chimeric antigen receptor (CAR-T) cell therapies, mainly target blood cancers like lymphoma, myeloma and leukemia, which have a tumor antigen -- like a flag or a signal -- on the surface of the cells so it is easy for immune cells to find and target the harmful cells. But many common cancers lack this clear, surface signal. Hinrichs' approach focuses on HPV tumors because they contain viral antigens that the immune system can easily recognize. / AFP PHOTO / SAUL LOEB (Photo credit should read SAUL LOEB/AFP/Getty Images)
{{::t('rf_licenses_include')}}

{{::t('gi_rf_includes')}}

  • {{ t('unlimited_print_runs')}}
  • {{ t('comprehensive_protection')}}
{{::t('how_can_i_use_this_image')}}
{{t('common_uses_include')}}
{{::t('common_uses')}}
{{t('cannot_be_used_for')}}
{{::t('forbidden_uses')}}
{{::t('esl_standard_editorial_rights')}}
{{::t('standard_rights')}}
{{::t('subject_to_content_license_agreement')}}
{{selectAgreementHeader}}
{{selectedOption.friendlyName}}
{{::t('premium_access_in_overage')}}{{::t('overage_tooltip')}}
{{size.teeShirtSize || size.label}}
{{size.pixels}} ({{size.localeUnits}})
{{size.dpi}} dpi|{{size.megapixels}}
{{formatPrice(size.price)}}{{formatPrice(size.discountPrice || size.price)}}{{size.discountPrice || size.price}}

{{sizeData()}}

{{formatPrice(size.price)}}{{formatPrice(size.discountPrice || size.price)}}{{size.discountPrice || size.price}}

{{t('new_bang_all_caps')}}
{{::t('errors.messages.enter_required_info')}} {{::t('errors.messages.enter_required_info')}}
{{::t('premium_access_view_only_tooltip')}}
{{::t('download_workflow.download_will_be_saved_to_dropbox')}}

{{::t('buy_card.calculate_price_cta')}}{{::t('buy_card.view_cart')}}

{{::t('site_specific.getty.request_preview')}}{{textForToggleButton(assetId)}}
{{::t('editorial_use_only_label')}}
{{::t('editorial_use_only_tooltip')}}
Details
Restrictions:Contact your local office for all commercial or promotional uses. Full editorial rights UK, US, Ireland, Italy, Spain, Canada (not Quebec). Restricted editorial rights elsewhere, please call local office.TO GO WITH AFP STORY by Kerry SHERIDAN: New paths to cure cancer emerge from immunotherapy trials
Credit:SAUL LOEB / Contributor
Editorial #:937109182
Collection:AFP
Date created:February 07, 2018
License type:Rights-managed
Release info:Not released. More information
Source:AFP
Barcode:AFP
Object name:AFP_12T7FZ
Max file size:5367 x 3544 px (17.89 x 11.81 in) - 300 dpi - 6.31 MB
1 item added to cart
CONTINUE SHOPPINGCHECKOUT